Abstract 360P
Background
Breast cancer is the the most frequently diagnosed cancer worldwide in women, with nearly two million new cases diagnosed in 2018. In the Philippines, breast cancer is the most common cancer among women. Upon diagnosis, the decision process differs from person to person. The patients then meet choices about surgical treatment and the need for adjuvant treatment, taking into consideration surgery, chemotherapy and radiation therapy to name a few. However, these decisions are not clear cut and a thorough discussion between the patient and the physician regarding treatment options taking into consideration the choice of the patient. This study aims to identify factors influencing treatment decisions among breast cancer patients in the Philippine General Hospital Cancer Institute - Medical Oncology Outpatient Clinic.
Methods
The study used a questionnaire and structured interview adapted from study done by Grunfeld, et.al. Descriptive statistics were utilized in the analysis of the data acquired from the recruited participants. This allowed identification of patient demographics, economic profile, cancer profile, sources of financial or medical assistance and summary of patient’s responses to identify the factors influencing treatment decisions among breast cancer patients.
Results
A total of 272 participants consented and included in the analysis of the study. This study identified high level of satisfaction with consultation to their attending physician, caring and sincere communication about prognosis and likelihood of benefit from treatment, family as person of influence, patient’s collaborative role in the decision-making process, desire of cure and trust with their doctors as factors of influence in accepting cancer treatment decisions.
Conclusions
Health practices and treatment decisions among Filipino breast cancer patients are widely affected by interplay of the following factors: family, community, doctor’s recommendations, patient’s satisfaction and participation in the decision-making, health care access and adverse treatments to name a few.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bobby de Guzman.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract